Business Context and Reporting Period
Company: Omeros Corporation (OMER)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Omeros is a clinical-stage biopharmaceutical company focused on complement-mediated diseases and addictive disorders. Key assets include narsoplimab (TA-TMA), zaltenibart (PNH/C3G), and the OMIDRIA royalty stream (discontinued operations).
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss (Continuing Ops) | $(21.2M) | $(37.1M) | $(84.7M) | $(146.1M) |
| Net Loss (Total) | $(30.9M) | $(32.2M) | $(89.8M) | $(125.5M) |
| Net Loss Per Share (Basic) | $(0.47) | $(0.56) | $(1.47) | $(2.15) |
| Cash & Short-Term Investments | $36.1M | $90.1M | $36.1M | $90.1M |
| Total Debt (Carrying Value) | $176.6M | $187.6M | $176.6M | $187.6M |
| Operating Cash Flow (9M) | $(76.3M) | $(119.8M) | $(76.3M) | $(119.8M) |
Note: Revenue is $0 as the company is pre-commercial for its pipeline assets. OMIDRIA royalties are classified as discontinued operations.
Material Changes vs. Prior Period
- Expense Reduction: Total costs and expenses decreased to $26.4M in Q3 2025 from $35.4M in Q3 2024. Research and Development (R&D) expenses dropped significantly ($16.0M vs $24.1M) due to the temporary pause of the Phase 3 zaltenibart program and wind-down of prior studies.
- Debt Restructuring: In May 2025, the company exchanged $70.8M of 2026 Notes for 2029 Notes and equitized $10.0M of 2026 Notes into common stock. This reduced the 2026 Notes principal balance from $97.9M to $17.1M.
- Discontinued Operations Volatility: Net loss from discontinued operations was $9.7M in Q3 2025 compared to income of $4.9M in Q3 2024. This shift was driven by a $13.4M non-cash remeasurement adjustment to the OMIDRIA contract royalty asset reflecting lower forecasted sales.
- Interest Expense: Net interest expense decreased significantly due to non-cash remeasurement gains on the OMIDRIA royalty obligation, offsetting higher contractual interest on the new 2029 Notes.
Guidance, Outlook, and Risks
- Novo Nordisk Transaction: On October 10, 2025, Omeros entered an Asset Purchase and License Agreement (APLA) with Novo Nordisk for zaltenibart. The deal includes a $240M upfront payment (expected Q4 2025), up to $410M in development milestones, and up to $1.3B in sales milestones. Proceeds will be used to repay the $67.1M Term Loan and fund operations.
- Regulatory Milestones:
- Narsoplimab (TA-TMA): FDA PDUFA date extended to December 26, 2025. EMA MAA submitted June 2025; opinion expected mid-2026.
- OMS527 (Cocaine Use Disorder): Clinical study targeted for H2 2026 pending FDA clearance.
- Liquidity & Going Concern: The filing states "substantial doubt" regarding the ability to continue as a going concern for one year from issuance without the Novo Nordisk transaction or additional financing. The company maintains a $25M liquidity covenant under its Credit Agreement, which is currently met ($36.1M cash/investments).
- Capital Raises: In Q3 2025, the company raised $20.3M via a registered direct offering and $9.0M via its At-The-Market (ATM) facility.
Investor Verification Checklist
- Novo Nordisk Closing: Verify the closing of the APLA in Q4 2025 and the receipt of the $240M upfront payment, which is critical for debt repayment and solvency.
- FDA Decision: Monitor the December 26, 2025 PDUFA decision for narsoplimab in TA-TMA.
- Debt Covenants: Confirm continued compliance with the $25M unrestricted cash covenant under the Credit Agreement until the Term Loan is repaid.
- OMIDRIA Remeasurement: Review future quarterly filings for volatility in discontinued operations due to OMIDRIA royalty asset/liability remeasurements.
- Equity Dilution: Track the impact of the 2029 Notes conversion feature and ongoing ATM sales on share count.